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Appropriate 
Screening for  
Leishmaniasis  
before  
Immunosuppressive   
Treatments
To  the  Editor:  We  read  with 
great interest the article by Xynos et 
al. reporting 2 cases of leishmaniasis 
in patients treated with biologic drugs 
(1). Although we agree with most of 
the  article,  we  are  not  totally  con-
vinced  that  serologic  analysis  alone 
could be used to screen for leishma-
niasis before initiation of biologic or 
immunosuppressive  treatments.  Evi-
dence indicates that serologic analy-
sis can identify only symptomatic or   
asymptomatic  cases  with  recent  and 
still active infection (2,3).
Leishmania  spp.  are  pathogens 
that infect hematopoietic cells, where 
they  establish  chronic  intracellular 
parasitism and survive for an infected 
person’s  lifetime.  In  leishmaniasis-
endemic  countries,  asymptomatic 
visceral leishmaniasis (VL) infections 
occur  more  frequently  than  clinical-
ly  apparent  VL  cases. An  estimated 
10%–20%  of  persons  with  asymp-
tomatic  infections  develop  clinically 
overt VL (4). The leishmanin skin test 
(LST) (Montenegro test), an intrader-
mal injection of a suspension of killed 
promastigotes, measures delayed hy-
persensitivity  reactions  and  appears 
to be the only screening test capable 
of detecting asymptomatic leishmania 
infections.
A positive LST result is thought 
to indicate durable cell-mediated im-
munity  after  asymptomatic  infection 
or clinical cure of VL. LST positivity 
may  appear  months  to  years  postin-
fection, but once positivity appears, it 
persists in immunocompetent patients. 
A survey of VL in Ethiopia showed 
LST positivity in 32.2% of the popu-
lation, but leishmania antibodies were 
found in only 4.1% (5).
Because different antigen prepa-
rations may affect test sensitivity, LST 
should use promastigotes of the Leish-
mania spp. present in an area. We be-
lieve that ideal screening for leishma-
niasis should include LST along with 
serologic analysis. Unfortunately, little 
data exist on the use of antileishmania 
therapies for LST-positive or serologi-
cally positive patients. VL with unusu-
al signs and symptoms may develop in 
immunocompromised  patients  with 
previous LST  positivity after immu-
nosuppressive treatments. Information 
about LST positivity is useful for call-
ing attention to this potential risk for 
VL that may have unusual manifesta-
tions in these persons.
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In  Response:  In  their  letter  re-
sponding  to  our  recently  published 
article (1) Cascio and Iaria spark an 
important  discussion  on  the  useful-
ness of screening for Leishmania in-
fection before administering biologic 
agents  or  other  immunosuppressive 
treatments to patients having autoim-
mune  rheumatic  diseases  and  living 
in areas where  Leishmania parasites 
are endemic (2). Although we agree 
in principle that early detection of as-
ymptomatic Leishmania infection will 
decrease the incidence of the disease 
in immunosuppressed patients, current 
diagnostic tools may have a limited (or 
restricted) role in detecting Leishma-
nia infection in this vulnerable patient 
population. Screening for leishmania-
sis has been hampered by the lack of 
a  standard  test.  Currently  available 
serologic methods have variable sen-
sitivities, specificities, and cross-reac-
tivities, depending on the species be-
ing tested and the region where tests 
are performed. Many experts believe 
that serologic tests may complement 
other existing diagnostic tools, raising 
cost-efficiency concerns, especially in 
financially deprived countries (3).
A  positive  leishmanin  skin  test 
(LST)  result  indicates  exposure  to 
Leishmania  spp.  and  is  generally 
thought to reflect a durable cell-me-
diated  immune  response.  No  cross-
reaction occurs in patients with Cha-
gas disease, but some cross-reactions 
are  found  in  patients  with  glandular 
tuberculosis  or  lepromatous  leprosy 
(4).  Sustained  positive  responses 
have been documented for up to 20 
years after exposure to the Leishma-
nia  parasite.  Nevertheless,  LST  has 
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limitations. In a longitudinal study of 
visceral leishmaniasis in Bangladesh, 
Bern et al. reported loss of LST sensi-
tivity attributed to antigen-production 
issues,  such  as  standardization  and 
documentation of sensitivity, potency, 
and  stability  of  leishmanin  antigens 
(5). Also, prior treatment with immu-
nosuppressive agents, which influence 
cell-mediated immunity, may decrease 
LST  prognostic potency similarly to 
changes  observed  for  the  tuberculin 
skin test in similar settings (6).
Variations  in  specificities  and 
sensitivities  limit  the  diagnostic  po-
tential  of  available  diagnostic  tools. 
The  context  of  immunosuppression 
further  contributes  to  the  diagnostic 
complications and increases the need 
for additional research in leishmania-
sis diagnostics.
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ANOTHER DIMENSION
Red Snappers
Erin E. McConnell
for a moment pretend
you are not
the infallible house staff,
but the latest admission—
hacking putrid sputum
from your soulful depths
or your festering chest,
depending on your mood. 
slapped with a mask,
you are secured in secluded rooms;
a paucity of guests,
but for the parade of absurd birds—
plastered in Haz-mat
lemon-yellow gowns,
and peach-colored beaks.
your meager dried-up sleep 
is aborted by 
bloodhungry fowl
covetous of mucus
you no longer produce.
your meals grow cold
waiting for you
in the anteroom of
your negative pressure purgatory.
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